These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24953794)

  • 1. Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial.
    Suhler EB; Lim LL; Beardsley RM; Giles TR; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Smith JR; Rosenbaum JT
    Ophthalmology; 2014 Oct; 121(10):1885-91. PubMed ID: 24953794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial.
    Suhler EB; Lim LL; Beardsley RM; Giles TR; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Smith JR; Rosenbaum JT
    JAMA Ophthalmol; 2014 May; 132(5):572-8. PubMed ID: 24652467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus.
    Londhe PJ; Kalyanpad Y; Khopkar US
    Indian J Dermatol Venereol Leprol; 2014; 80(4):300-5. PubMed ID: 25035353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener's).
    Recillas-Gispert C; Serna-Ojeda JC; Flores-Suárez LF
    Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2279-84. PubMed ID: 26507398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.
    Murphy CC; Ayliffe WH; Booth A; Makanjuola D; Andrews PA; Jayne D
    Ophthalmology; 2004 Feb; 111(2):352-6. PubMed ID: 15019389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
    Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT
    Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab therapy for refractory idiopathic scleritis.
    Bogdanic-Werner K; Fernandez-Sanz G; Alejandre Alba N; Ferrer Soldevila P; Romero-Bueno FI; Sanchez-Pernaute O
    Ocul Immunol Inflamm; 2013 Aug; 21(4):329-32. PubMed ID: 23662782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gevokizumab in the Treatment of Autoimmune Non-necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial.
    Knickelbein JE; Tucker WR; Bhatt N; Armbrust K; Valent D; Obiyor D; Nussenblatt RB; Sen HN
    Am J Ophthalmol; 2016 Dec; 172():104-110. PubMed ID: 27663070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
    El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP
    J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
    Ghanima W; Khelif A; Waage A; Michel M; Tjønnfjord GE; Romdhan NB; Kahrs J; Darne B; Holme PA;
    Lancet; 2015 Apr; 385(9978):1653-61. PubMed ID: 25662413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab therapy for the treatment of refractory ocular inflammatory disease.
    Sobrin L; Kim EC; Christen W; Papadaki T; Letko E; Foster CS
    Arch Ophthalmol; 2007 Jul; 125(7):895-900. PubMed ID: 17620567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in the Treatment of Refractory Noninfectious Scleritis.
    Cao JH; Oray M; Cocho L; Foster CS
    Am J Ophthalmol; 2016 Apr; 164():22-8. PubMed ID: 26766304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.
    Letko E; Yeh S; Foster CS; Pleyer U; Brigell M; Grosskreutz CL;
    Ophthalmology; 2015 May; 122(5):939-48. PubMed ID: 25638011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
    Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
    J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases.
    Miserocchi E; Pontikaki I; Modorati G; Gattinara M; Meroni PL; Gerloni V
    Autoimmun Rev; 2011 Nov; 11(1):35-9. PubMed ID: 21763790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up.
    Cianchini G; Lupi F; Masini C; Corona R; Puddu P; De Pità O
    J Am Acad Dermatol; 2012 Oct; 67(4):617-22. PubMed ID: 22243765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis.
    Leiper K; Martin K; Ellis A; Subramanian S; Watson AJ; Christmas SE; Howarth D; Campbell F; Rhodes JM
    Gut; 2011 Nov; 60(11):1520-6. PubMed ID: 21471566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.